Ambulatory surgery centres (ASCs) are self-contained medical facilities that specialise in surgical, diagnostic, and preventive procedures that do not necessitate hospitalisation. The cost-effectiveness of ASCs saves governments, third-party payers, and patients money because these facilities provide a lower-cost site of care than hospital outpatient departments.
NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Spine Surgery Robots Market is Set to Exceed Valuation of USD 139.93 Million with Potential Growth Rate of 8.40% by 2029 | Analysed by Size Share, Trends, Key Players & Future Growth Outlook
Data Bridge Market research has recently released expansive research titled “Global Spine Surgery Robots Market” which guarantees you will remain better informed than your competition. Spine Surgery Robots Market document provides a comprehensive synopsis of the study for the market and how it is impacting the Healthcare industry. By applying best-practice models and research methodologies, a complete market analysis is performed in this market report to ensure that the report provides accurate market segmentation and insights for the success of the client’s business. What is more, the trends in consumer and supply chain dynamics are also recognized, and then accordingly strategies for marketing, promotion, and sales are interpreted for extreme success. Businesses can thrive in this swiftly changing marketplace by adopting a credible Spine Surgery Robots Market research report.
Data Bridge Market Research analyses that the spine surgery robots market is expected to reach USD 139.93 million by the year 2029, at a CAGR of 8.40% during the forecast period. “Healthcare providers” accounts for the largest end-user segment in the spine surgery robots market owing to the presence of government mandates and rise in healthcare costs.
Grab PDF Sample of Spine Surgery Robots Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-spine-surgery-robots-market&GNW/15Aug2022
Historic Years - 2020 (Customizable to 2014 - 2019)
Surgeons can now perform complex surgical procedures with greater precision thanks to surgical robots. They are most commonly used in gynaecological, urological, orthopaedic, general, and neurosurgery procedures, as well as other minimally invasive surgeries.
In recent years, with the introduction of robotic spinal surgery systems, surgeons can plan the surgical procedure ahead of time and perform a more accurate procedure. The technology can tailor procedures to each patient's unique anatomy. The physician must perform the actual surgery, but the robotic spinal surgery system guides the surgeon's tools according to a predetermined method to place the implants safely and accurately in the exact pre-planned locations. A robotic spinal surgery system employs robotic arms that are controlled by surgeons.
Some of the major players operating in the spine surgery robots market are
Johnson and Johnson Services Inc.
Orion Health group of companies
Access Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-spine-surgery-robots-market?GNW/15Aug2022
Stryker acquired OrthoSensor and its Verasense intraoperative sensor technology in January 2021 to improve the ortho giant's Mako robots.
TransEnterix received CE Mark approval in January 2021 for its Intelligent Surgical Unit, which adds AI-based capabilities and machine vision capabilities to TransEnterix's Senhance robotic surgery system.
Sytrker Corporation received regulatory approval in Japan for the Mako robotic surgery system for partial knee indication in January 2020.
Titan Medical joined forces with Teleflex Incorporated in March 2019. The collaboration's goal was to create a robotic ligation technology. Teleflex's market-leading polymer ligation technology will be integrated into Titan's development-stage, single-port robotic surgery system as part of this collaboration.
Ambulatory surgery centres (ASCs) are self-contained medical facilities that specialise in surgical, diagnostic, and preventive procedures that do not necessitate hospitalisation. The cost-effectiveness of ASCs saves governments, third-party payers, and patients money because these facilities provide a lower-cost site of care than hospital outpatient departments.
Market Dynamics: - Spine surgery robots
The rise in the adoption of robotic health technology
Surging investment in the development of new and advanced technology, increasing adoption of robotic technology, rising awareness of the benefits associated with minimally invasive surgery, an increase in the number of surgical procedures, and hospitals' expanding purchasing power are some of the factors that will drive the growth of the spine surgery robots market during the forecast period. Increased applications from emerging economies, on the other hand, will create new and ample opportunities for the growth of the spine surgery robots market during the forecast period.
The Perks of Robotic-Assisted Surgery
Globally, the demand for minimally invasive surgeries (MIS) is increasing, owing to the benefits associated with these procedures, which include smaller incisions, fewer cuts, less scarring, less pain, increased safety, shorter recovery periods, and significant cost savings. Robotic minimally invasive surgery enhances these benefits by providing greater accuracy, repeatability, control, and efficiency.
Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market
Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the spine surgery robots market.
Gain More Insights into the Spine Surgery Robots Market, Visit @ https://www.databridgemarketresearch.com/reports/global-spine-surgery-robots-market?GNW/15Aug2022
The countries covered in the spine surgery robots market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the spine surgery robots market due to the increasing occurrences of spinal cord injuries, while Asia-Pacific is expected to grow at the fastest rate during the forecast period due to increased awareness about healthcare management and rising healthcare expenditure by people.
For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-spine-surgery-robots-market&GNW/15Aug2022
Spine Biologics Market, By Product (Bone Allografts, Bone Graft Substitute, Platelet Rich Plasma, Bone Marrow Aspirate Therapy), Surgery Type (Anterior Cervical Discectomy and Fusion (ACDF), Transforamenal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF)), End-User (Hospitals, Spinal Surgery Centers, Orthopedic Clinics, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-spine-biologics-market
Medical Robotic System Market, By Deployment Type (On-premises, Cloud Based), Products and Services (Instrument and Accessories, Robotic Systems and Services), Application (Neurology, Orthopedics, Laparoscopy, Special Education), End Users (Hospitals, Ambulatory Surgical Centers, Rehabilitation Centers, Others) https://www.databridgemarketresearch.com/reports/global-medical-robotic-systems-market
North America Medical Robotic Systems Market, By Product (Instrument and Accessories, Robotic Systems), By Application (Laparoscopy, Orthopedic Surgery, Pharmacy Applications, Neurosurgery, Other Applications) https://www.databridgemarketresearch.com/reports/north-america-medical-robotic-systems-market
Europe Medical Robotic Systems Market, By Product (Instruments & Accessories, Robotic Systems), Application (Laparoscopy, Orthopedic Surgery, Pharmacy Applications, Neurosurgery, Other Applications), Country (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) https://www.databridgemarketresearch.com/reports/europe-medical-robotic-systems-market
Asia-Pacific Medical Robotic Systems Market, By Product (Instruments & Accessories, Robotic Systems), Application (Laparoscopy, Orthopedic Surgery, Pharmacy Applications, Neurosurgery, Other Applications), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) https://www.databridgemarketresearch.com/reports/asia-pacific-medical-robotic-systems-market
Medical Robots Market, By Type (External Large Robots, Geriatric Robot, Assistive Robots, Miniature in Vivo Robots), Product (Surgical Robots, Rehabilitation Robots, Hospital and Pharmacy Robots, Bio Robotics, Non-invasive Radio Surgery Robots, Telepresence Robots, Medical Transportation Robots, Sanitation and Disinfectant Robots), Modality (Compact, Portable), Components (Actuators, Sensors, Robot Controller, Patient Cart, Surgeon Console, Vision Cart, Dispensing System and Additional Products), Application (Research, Clinic, Pharmacy, and Others), End User (Hospitals, Specialty Clinics, Research Institutes, Ambulatory Surgical Centers, Laboratories, Rehabilitation Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, Others) https://www.databridgemarketresearch.com/reports/global-medical-robots-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood. Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high. Related: Aeglea BioTherapeutics Shares
Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.
The Food and Drug Administration approved a new depression pill from Axsome Therapeutics on Friday, and AXSM stock catapulted higher.
U.S. based monkeypox vaccine manufacturer targets December for first batch of doses for delivery.
BlackCloak CEO Chris Pierson joins Yahoo Finance Live to discuss Apple’s security vulnerabilities, why Apple users should update their devices, and the outlook for cyberattacks.
(Bloomberg) -- Qualcomm Inc. is taking another run at the market for server processors, according to people familiar with its plans, betting it can tap a $28 billion industry and decrease its reliance on smartphones.The company is seeking customers for a product stemming from last year’s purchase of chip startup Nuvia, according to the people, who asked not to be identified because the discussions are private. Amazon.com Inc.’s AWS business, one of the biggest server chip buyers, has agreed to t
A 60-year-old real estate development, investment, and management firm with over 19,100 units under management in 19 U.S. states has signed a contract for Knightscope, Inc's (NASDAQ: KSCP) K1 and K5 Autonomous Security Robots (ASRs). Advanced security technology company Knightscope builds fully autonomous security robots that deter, detect, and report. Similar to the RoboCop movie, which identifies and apprehends a criminal in the crowd, these security robots help remote monitoring from anywhere
(Bloomberg) -- A two-year-old Shanghai-based developer of chip design software was behind an attempt to buy a British firm that regulators blocked with little explanation, the latest example of Britain’s increasing hostility toward Chinese investment.Super Orange HK Holding Ltd. was blocked from buying Bristol-based chip design software provider Pulsic Ltd., the British Business Secretary announced in a brief statement Wednesday. But that firm is in reality controlled by little-known Shanghai Un
Bloomberg News reported Wednesday that the tech giant will update its flagship smartphones amid a busy fall product rollout that includes three new Apple Watch models and multiple new versions of Macs and iPads.
The drug, which can take effect within a week, uses a different mechanism than traditional treatments for depression.
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies. Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (Ansuvimab, mAb114) and Inmazeb (REGN-EB3). Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Inmazeb became the first treatment for the ebola virus when it received FDA approval in October 2020. Merck & Co Inc's (NYSE: MRK)
Security experts advise users to update their devices immediately to avoid an attack.
As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances. It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development. Meanwhile, Sarepta Therapeutics currently boasts over 37 pipeline programs, including 21 assets in gene therapy alone.
Statement Highlights: A “state of the science” review details the most reported symptoms of 6 cardiovascular diseases (CVDs): heart attack, heart failure, valve disease, stroke, heart rhythm disorders, and peripheral artery and vein disease (PAD and...
Wedbush Managing Director and Senior Equity Analyst Dan Ives joins Yahoo Finance Live to assess Apple's device software on news of cybersecurity flaws, device updates, and the growth in Apple's other key sectors.
NBC News Chief Foreign Correspondent Richard Engel announced Thursday that his son Henry, 6, has died. “Our beloved son Henry passed away.
Vulnerability may already have been used by hackers to take control of people’s phones
Verve’s effort to lower patients’ levels of bad cholesterol with a single injection is gradually making clinical progress and would be a significant upgrade from statins and other medicines currently available.
The U.S. government asks Bavarian Nordic, the sole manufacturer of a monkeypox vaccine, to find new partners.
The ads are everywhere — as are the inflated claims: Special shampoos and treatments, sometimes costing thousands of dollars, will make hair grow. But many dermatologists who specialize in hair loss say that most of these products do not work. “There is an endless array of useless hair-growth remedies,” often at “significant cost,” said Dr. Brett King, a dermatologist at Yale School of Medicine. Yet, he added, “because people are desperate, such hair growth remedies continue to abound.” But ther